(Q83799893)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21471993%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

title

Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21471993%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

author name string

S Vosslamber

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21471993%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

L F van der Voort

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21471993%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

I J van den Elskamp

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21471993%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

R Heijmans

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21471993%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

C Aubin

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21471993%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

B M J Uitdehaag

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21471993%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

J B A Crusius

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21471993%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

T C T M van der Pouw Kraan

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21471993%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

M Comabella

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21471993%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

P L De Jager

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21471993%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

J Killestein

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21471993%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

C H Polman

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21471993%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

C L Verweij

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21471993%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

publication date

7 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21471993%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21471993%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21471993%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21471993%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

page(s)

466-472

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21471993%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/gene.2011.18

27 January 2020

exact match

0 references

cites work

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2011.18

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2011.18

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2011.18

7 January 2021

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2011.18

7 January 2021

A subtype of multiple sclerosis defined by an activated immune defense program

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2011.18

7 January 2021

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2011.18

7 January 2021

A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2011.18

7 January 2021

The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2011.18

7 January 2021

IRF-5 is a mediator of the death receptor-induced apoptotic signaling pathway

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2011.18

7 January 2021

A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2011.18

7 January 2021

Systemic lupus erythematosus: all roads lead to type I interferons

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2011.18

7 January 2021

Association of IRF5 polymorphisms with activation of the interferon alpha pathway

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2011.18

7 January 2021

Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2011.18

7 January 2021

Defining interferon beta response status in multiple sclerosis patients.

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2011.18

7 January 2021

Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2011.18

7 January 2021

Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2011.18

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2011.18

7 January 2021

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2011.18

7 January 2021

Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2011.18

7 January 2021

Visual analysis of serial T2-weighted MRI in multiple sclerosis: intra- and interobserver reproducibility

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2011.18

7 January 2021